La cadena de opciones muestra datos clave de las opciones de acciones de BioRestorative Therapies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioRestorative Therapies..

BioRestorative Therapies (NASDAQ:BRTX) Bolsa, Cadena de Opciones

BioRestorative Therapies

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

Press Releases

BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

BioRestorative Announces Share Repurchase Program

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show"

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

BRTX

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evogene

Galecto

Imunon

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Marker Therapeutics

OSR Holdings

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

BioRestorative Therapies

BioRestorative Therapies (BRTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL